Nils Confer, Ph.D., M.B.A.
Nils is the vice president of medical affairs for Origin Biosciences and supports BridgeBio in its newborn screening and point of care diagnostics efforts. During his career he has progressed from large pharmaceutical companies to early stage pipeline programs and biotechnology companies, while consistently involved with rare genetic diseases and medical affairs activities. Dr. Confer has nearly 20 years of research and pharmaceutical/biotechnology industry experience spanning Novartis, Shire, Raptor and Horizon Pharmaceuticals, and involving rare diseases such as cryopyrin-associated periodic syndrome, Gaucher, Fabry, Hunter, Sanfilippo, metachromatic leukodystrophy, mitochondrial diseases, nephropathic cystinosis and now molybdenum cofactor deficiency type A. Prior to industry he was at the University of Texas Southwestern Medical School in the department of molecular pathology conducting research on rare genetic diseases, mainly the roles of atypical DNA polymerases and their associated post-translational modifications in the disease xeroderma pigmentosum. He holds a Ph.D. from the University of North Texas in biomedical sciences with an emphasis in protein biochemistry and an M.B.A. from the University of Texas with a certificate in Asian business studies.